Role of nuclear factor-kB in the regulation of c-myc gene transcription. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Role of nuclear factor-kB in the regulation of c-myc gene transcription.

Diss Abstr Int [B]; 53(3):1192 1992. Unique Identifier : AIDSLINE ICDB/93687843
Duyao MP; Boston Univ.


Abstract: The c-myc proto-oncogene has been implicated in cell proliferation, differentiation, and neoplasia. Its expression is largely regulated at the level of transcription. I have mapped several regions upstream of the murine c-myc promoter which interact with nuclear proteins from the murine B-cell lymphoma cell line WEHI 231. These interactions were decreased upon antiserum-induced growth arrest of these cells and during the down-modulation of c-myc gene transcription. One of these regions, termed URE, is located -1101 to -1081 bp relative to the first transcription start site. Interaction of nuclear factor kappa B (NFkB) with the URE was demonstrated based on (1) binding competition with oligonucleotides containing known NFkB sites from various genes, (2) induction of binding during differentiation of 70Z/3 pre-B cells to B cells, (3) induction of binding following treatment of cytoplasmic pre-B-cell extracts with detergents, and (4) the enhancement of binding by GTP. Upon induction of NFkB, stimulation of transiently transfected thymidine kinase promoter-driven chloramphenicol acetyl transferase (CAT) gene constructs containing multiple copies of the URE indicated that the URE is a functional NFkB element, mediating positive activation of transcription. The URE is one of two NFkB sites present in the gene; the other is termed IRE and is located within exon 1 at +440 to +459 bp. To assess the role of NFkB in regulation of c-myc transcription, the effect of the human T-cell leukemia virus type I tax protein, which induces NFkB expression, was examined. In transient cotransfection analyses of Jurkat or HeLa cells, tax transactivated murine c-myc promoter/exon 1 CAT constructs containing wild-type URE and IRE elements. In contrast, tax activation of mutated myc CAT constructs, in which the URE and IRE were altered to prevent binding of NFkB, was significantly reduced. Furthermore, a mutant tax protein, unable to induce NFkB, failed to activate these constructs. Thus, tax transactivation of c-myc is mediated through the interaction of NFkB. These findings suggest that activation of c-myc expression via activation of NFkB may play an important role in c-myc transcription. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No. AAD92-20756.)
Keywords: *Cell Division Chloramphenicol Acetyltransferase/GENETICS Exons Gene Expression Regulation Gene Products, tax/GENETICS Lymphoma, B-Cell/GENETICS NF-kappa B/GENETICS Promoter Regions (Genetics) Proto-Oncogene Proteins c-myc/*GENETICS *Transcription, Genetic Tumor Cells, Cultured THESISKWDcelldivisionchloramphenicolacetyltransferase/geneticsexonsgeneexpressionregulationgeneproducts,tax/geneticslymphoma,b-cell/geneticsnf-kappab/geneticspromoterregions(genetics)proto-oncogeneproteinsc-myc/KWDgeneticsKWDtranscription,genetictumorcells,culturedthesis
930228
M9320862

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .